These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 16449119

  • 1. Cost-effectiveness of extending cervical cancer screening intervals among women with prior normal pap tests.
    Kulasingam SL, Myers ER, Lawson HW, McConnell KJ, Kerlikowske K, Melnikow J, Washington AE, Sawaya GF.
    Obstet Gynecol; 2006 Feb; 107(2 Pt 1):321-8. PubMed ID: 16449119
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.
    Manser R, Dalton A, Carter R, Byrnes G, Elwood M, Campbell DA.
    Lung Cancer; 2005 May; 48(2):171-85. PubMed ID: 15829317
    [Abstract] [Full Text] [Related]

  • 3. Report from the CDC. Pap test intervals used by physicians serving low-income women through the National Breast and Cervical Cancer Early Detection Program.
    Cooper CP, Saraiya M, McLean TA, Hannan J, Liesmann JM, Rose SW, Lawson HW.
    J Womens Health (Larchmt); 2005 Oct; 14(8):670-8. PubMed ID: 16232098
    [Abstract] [Full Text] [Related]

  • 4. The cost-effectiveness of cervical screening in Australia: what is the impact of screening at different intervals or over a different age range?
    Anderson R, Haas M, Shanahan M.
    Aust N Z J Public Health; 2008 Feb; 32(1):43-52. PubMed ID: 18290913
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of a tailored intervention to increase screening in HMO women overdue for Pap test and mammography services.
    Lynch FL, Whitlock EP, Valanis BG, Smith SK.
    Prev Med; 2004 Apr; 38(4):403-11. PubMed ID: 15020173
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and cost-effectiveness of nationwide cervical cancer screening in Taiwan.
    Koong SL, Yen AM, Chen TH.
    J Med Screen; 2006 Apr; 13 Suppl 1():S44-7. PubMed ID: 17227642
    [Abstract] [Full Text] [Related]

  • 7. High-grade cervical abnormalities and screening intervals in New South Wales, Australia.
    Schindeler S, Morrell S, Zuo Y, Baker D.
    J Med Screen; 2008 Apr; 15(1):36-43. PubMed ID: 18416954
    [Abstract] [Full Text] [Related]

  • 8. Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India.
    Okonkwo QL, Draisma G, der Kinderen A, Brown ML, de Koning HJ.
    J Natl Cancer Inst; 2008 Sep 17; 100(18):1290-300. PubMed ID: 18780864
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong.
    Kim JJ, Leung GM, Woo PP, Goldie SJ.
    J Public Health (Oxf); 2004 Jun 17; 26(2):130-7. PubMed ID: 15284314
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of adding human papilloma virus testing to a managed care cervical cancer screening program.
    Lonky NM, Hunter MI, Sadeghi M, Edwards G, Bajamundi K, Monk BJ.
    J Low Genit Tract Dis; 2007 Oct 17; 11(4):258-64. PubMed ID: 17917570
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE, Karnon J, Smith RE, Johnston SR, Brandman J, Sung JC, Gross PE.
    Am J Manag Care; 2006 Jul 17; 12(7):374-86. PubMed ID: 16834524
    [Abstract] [Full Text] [Related]

  • 12. De novo establishment and cost-effectiveness of Papanicolaou cytology screening services in the Socialist Republic of Vietnam.
    Suba EJ, Nguyen CH, Nguyen BD, Raab SS, Viet/American Cervical Cancer Prevention Project.
    Cancer; 2001 Mar 01; 91(5):928-39. PubMed ID: 11251944
    [Abstract] [Full Text] [Related]

  • 13. When does quality-adjusting life-years matter in cost-effectiveness analysis?
    Chapman RH, Berger M, Weinstein MC, Weeks JC, Goldie S, Neumann PJ.
    Health Econ; 2004 May 01; 13(5):429-36. PubMed ID: 15127423
    [Abstract] [Full Text] [Related]

  • 14. Modeling cost-effectiveness of cervical cancer screening in Hungary.
    Vokó Z, Nagyjánosi L, Margitai B, Kövi R, Tóth Z, László D, Kaló Z.
    Value Health; 2012 Jan 01; 15(1):39-45. PubMed ID: 22264970
    [Abstract] [Full Text] [Related]

  • 15. The program cost and cost-effectiveness of screening men for Chlamydia to prevent pelvic inflammatory disease in women.
    Gift TL, Gaydos CA, Kent CK, Marrazzo JM, Rietmeijer CA, Schillinger JA, Dunne EF.
    Sex Transm Dis; 2008 Nov 01; 35(11 Suppl):S66-75. PubMed ID: 18830137
    [Abstract] [Full Text] [Related]

  • 16. Clinical and cost implications of new technologies for cervical cancer screening: the impact of test sensitivity.
    Hutchinson ML, Berger BM, Farber FL.
    Am J Manag Care; 2000 Jul 01; 6(7):766-80. PubMed ID: 11067374
    [Abstract] [Full Text] [Related]

  • 17. Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it?
    Havrilesky LJ, Sanders GD, Kulasingam S, Myers ER.
    Gynecol Oncol; 2008 Nov 01; 111(2):179-87. PubMed ID: 18722004
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness analysis of endometrial cancer prevention strategies for obese women.
    Kwon JS, Lu KH.
    Obstet Gynecol; 2008 Jul 01; 112(1):56-63. PubMed ID: 18591308
    [Abstract] [Full Text] [Related]

  • 19. Cost effectiveness of cholesterol-lowering drugs: a review of the evidence.
    Thorvik E, Aursnes I, Kristiansen IS, Waaler HT.
    Wien Klin Wochenschr; 1996 Jul 01; 108(8):234-43. PubMed ID: 8686314
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of a community-based screening programme for chronic atrial fibrillation in Japan.
    Maeda K, Shimbo T, Fukui T.
    J Med Screen; 2004 Jul 01; 11(2):97-102. PubMed ID: 15153326
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.